Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent In Vitro and In Vivo Activity Against Respiratory Syncytial Virus

This article, published in The Journal of Infectious Diseases, details a preclinical study evaluating the ability of a humanized monoclonal antibody, MEDI-493 (later named palivizumab and marketed at Synagis®), to recognize a conserved neutralizing epitope on the F glycoprotein of respiratory syncytial virus (RSV). Study results indicated that pretreatment in cotton rats with MEDI-493 resulted in a 99 percent reduction of lung RSV titers at a dose of 2.5 mg/kg. MEDI-493 also did not induce increased RSV infection under challenge, making it a promising candidate for the prevention of RSV.

Author(s): Johnson S, Oliver C, Prince GA, et al.

Published: 1997

  • Visit web page (English)

    (Located at jid.oxfordjournals.org)

    Citation: Johnson S, Oliver C, Prince GA, et al. Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent In Vitro and In Vivo Activity Against Respiratory Syncytial Virus. The Journal of Infectious Diseases. 1997;176(5):1215-1224.